---
document_datetime: 2023-09-21 19:10:51
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps/cyanokit-epar-procedural-steps-taken-authorisation_en.pdf
document_name: cyanokit-epar-procedural-steps-taken-authorisation_en.pdf
version: success
processing_time: 0.3839321
conversion_datetime: 2025-12-28 01:46:48.72816
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## BACKGROUND INFORMATION ON THE PROCEDURE

## 1. Submission of the dossier

The  applicant  Merck  Sant√©  S.A.S.  submitted  on  29  November  2006  an  application  for  Marketing Authorisation  to  the  European  Medicines  Agency  (EMEA)  for  Cyanokit,  through  the  centralised procedure under Article 3 (2) (b) of Regulation (EC) No 726/2004, based on interest of patients at Community level. The eligibility to the centralised procedure was agreed upon by the EMEA/CHMP on 27 April 2006.

The legal basis for this application refers to:

Article 8(3) of Directive 2001/83/EC, as amended - complete and independent application

## Licensing status:

Cyanokit has been given a Marketing Authorisation in France (1996), Hong Kong (1999) and USA (2006)

The Rapporteur and Co-Rapporteur appointed by the CHMP were:

Rapporteur:

Dr. Pierre Demolis

Co-Rapporteur:

Dr. Ian Hudson

## 2. Steps taken for the assessment of the product

- The application was received by the EMEA on 29 November 2006.
- The Rapporteur's first Assessment Report was circulated to all CHMP members on 20 March 2007. The Co-Rapporteur's first Assessment Report was circulated to all CHMP members on 16 March 2007.
- The procedure started on 27 December 2006.
- During  the  meeting  on  23-26  April  2007,  the  CHMP  agreed  on  the  consolidated  List  of Questions to be sent to the applicant. The final consolidated List of Questions was sent to the applicant on  27 April 2007.
- The applicant submitted the responses to the CHMP consolidated List of Questions on 11 July 2007.
- The Rapporteurs circulated the Joint Assessment Report on the applicant's responses to the List of Questions to all CHMP members on  24 August 2007.
- During the meeting on  17 - 20 September 2007, the CHMP, in the light of the overall data submitted  and  the  scientific  discussion  within  the  Committee,  issued  a  positive  opinion  for granting a Marketing Authorisation to Cyanokit on 20 September 2007. The applicant provided the  letter  of  undertaking  on  the  follow-up  measures  to  be  fulfilled  post-authorisation  on  18 September 2007.
- The CHMP opinions were forwarded, in all official languages of the European Union, to the European Commission, which adopted the corresponding Decisions on 23 November 2007.